Hikma Pharmaceuticals PLC - Back to Homepage

Keep yourself updated about Hikma

News Search

Search for a news item according to period of time or category.

Ensuring the Sustainability of our Business

Download Hikma's latest CR Report

26 February 2015

Hikma signs exclusive license agreement with Azanta for Nimoral

London, 26 February 2015 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today announces the signing of an exclusive license agreement with specialty pharmaceutical company Azanta A/S for its proprietary cancer product Nimoral (nimorazole). Nimoral is a hypoxic radiosensitizer to enhance the effect of radiotherapy in head and neck cancer patients. The product is currently in Phase 3 clinical development and is being made available under named patient programs throughout the world.

London, 26 February 2015 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today announces the signing of an exclusive license agreement with specialty pharmaceutical company Azanta A/S for its proprietary cancer product Nimoral (nimorazole). Nimoral is a hypoxic radiosensitizer to enhance the effect of radiotherapy in head and neck cancer patients. The product is currently in Phase 3 clinical development and is being made available under named patient programs throughout the world.

Under the terms of the agreement, Hikma will have the exclusive rights to register, manufacture, distribute and market Nimoral in 20 markets in the MENA region including Turkey, leveraging Hikma’s strong local presence and regulatory expertise, with over 1,800 sales and marketing reps across the region.

Mazen Darwazah, Hikma’s Vice Chairman and CEO of MENA and Emerging Markets said, “Hikma is committed to improving the treatment of cancer in the MENA region through the development of our oncology product portfolio.  This partnership gives us access to a novel, oral anticancer treatment with excellent potential and reinforces our commitment to growing our portfolio through strong partnerships.  We look forward to the Phase 3 results for Nimoral and we are very pleased to be working with Azanta to bring this critically needed therapy to the MENA region.”

Dr. Claus Møller, Chief Executive Officer of Azanta, commented: "We are very pleased to enter this significant agreement with Hikma.  We believe Hikma will be an excellent partner for us for Nimoral in the MENA region, which has a population of more than 380 million people or 6% of the world population.  We will immediately begin transferring our technology to Hikma to enable them to provide Nimoral to patients in MENA.”

-- ENDS --

About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe.  In 2013, Hikma achieved revenues of $1,365 million and profit attributable to shareholders of $212 million.

About Azanta A/S
Azanta A/S is a privately owned Danish specialty pharma company primarily operating within oncology, women´s health and addiction medicine.  The vision of Azanta A/S is to become an international market leader within specialty pharma products and innovative pharmaceutical products.  Azanta A/S currently markets or makes available a string of specialty pharmaceutical products, including Nimoral, a hypoxic radiosensitizer for the treatment of head and neck cancer patients undergoing primary radiotherapy, and Angusta for labour induction.  In addition, Azanta A/S has a portfolio of low risk development projects for commercialisation within the near future.  For further information, please visit www.azanta.com.

Enquiries:

Hikma Pharmaceuticals PLC  
Susan Ringdal, VP Corporate
Strategy and Directors
of Investor Relations
+44 (0)20 7399 2760/ +44 7776 477050
Lucinda Henderson, Deputy
Director of Investor Relations
+44 (0)20 7399 2765/ +44 7818 060211
FTI Consulting  
Ben Atwell/ Matthew Cole/ Julia Phillips +44 (0)20 3727 1000
Press Release
+ more
Print page

Corporate

16 February 2015

Hikma Pharmaceuticals First Jordanian Site to Receive ISO 50001 Certification

Amman, 16 February 2015 - Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today announced that it has attained the ISO 50001 certification in recognition of its dedication to improving its energy management system (EnMS) over the past three years for its Jordan manufacturing operations. This achievement positions Hikma as the first pharmaceutical company in the Middle East and the first Jordanian site to obtain the ISO 50001 certification, which enables organizations to continually enhance energy performance, efficiency, use and consumption.

Amman, 16 February 2015 - Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today announced that it has attained the ISO 50001 certification in recognition of its dedication to improving its energy management system (EnMS) over the past three years for its Jordan manufacturing operations. This achievement positions Hikma as the first pharmaceutical company in the Middle East and the first Jordanian site to obtain the ISO 50001 certification, which enables organizations to continually enhance energy performance, efficiency, use and consumption.

The certification was granted following a comprehensive on-site inspection and thorough evaluation process covering Hikma’s energy management documents, procedures and upcoming strategy for 2015.

In addition to the ISO 50001 for energy management, Hikma had previously attained the ISO 9001 for quality management, ISO 14001 for environmental management, as well as the OHSAS 18001 for occupational health and safety.

Furthermore, Hikma periodically reports on various gas emissions and environmental outputs to demonstrate how it is improving its impact on the environment and aligning its operations to international standards. These reports are submitted to global entities such as the United Nations Global Compact, Carbon Disclosure Project and Global Reporting Initiative.

Mazen Darwazeh, Vice Chairman, President and CEO, MENA and Emerging Markets of Hikma said: “Being the first Jordanian site to receive the ISO 50001 certification is a distinct honor that spurs us to do all that is in our power to ensure that Hikma continues to carry out eco-friendly operations,” commented. “Over the past few years, we have been wholly committed to mitigating our energy consumption and gas emissions to reduce our ecological footprint in line with global best practices. By doing so, we have succeeded in establishing an internal culture at Hikma that promotes environmental sustainability and conscientiousness.” 

-- ENDS --

About Hikma
Hikma Pharmaceuticals is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based principally in the Middle East and North Africa (MENA) region, where it is a market leader, the United States and Europe. In December 2013, Hikma had 7,067 employees worldwide.

Enquiries:

Hikma Pharmaceuticals PLC  
Hana Ramadan, Director of Corporate Communication +962 6 5802900 ext. 313
Dana Shekem, Marketing Communication Specialist +962 6 5802900 ext. 356
Press Release
+ more
Print page

Corporate

27 January 2015

Hikma partners against corruption and supports MENA growth markets at WEF

Amman, 27 January 2015 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, joined the 45th World Economic Forum (WEF) Annual Meeting in Davos-Klosters, Switzerland, held on January 21 - 24, 2015, to provide insights on the impact of recent societal, political and economic developments on growth markets in the Arab World. Serving as a WEF Regional Associate for the second consecutive year, Hikma was one of 2,540 business, government, academic and civil society leaders to convene this year to explore solutions for pressing international, regional and industry issues within ‘The New Global Context' - the Forum's theme - as brought on by breakthrough technologies, demographic shifts and political transformations.

Amman, 27 January 2015 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, joined the 45th World Economic Forum (WEF) Annual Meeting in Davos-Klosters, Switzerland, held on January 21 - 24, 2015, to provide insights on the impact of recent societal, political and economic developments on growth markets in the Arab World. Serving as a WEF Regional Associate for the second consecutive year, Hikma was one of 2,540 business, government, academic and civil society leaders to convene this year to explore solutions for pressing international, regional and industry issues within ‘The New Global Context' - the Forum's theme - as brought on by breakthrough technologies, demographic shifts and political transformations.

Representing Hikma, Mazen Darwazeh, Vice Chairman, President and CEO of MENA and Emerging Markets, participated as a discussion leader in the ‘Arab World Growth Markets' session alongside Jordan's Minister of Finance, Umayya Toukan; the Palestinian National Authority's Deputy Prime Minister and Minister of Economy, Mohammad Mustafa; and Dana Gas PJSC's CEO, Patrick Allman-Ward. During the session, Darwazah elaborated on the economic consequences of falling oil prices; the potential of cross-sector and public-private integration; as well as the need for greater investment in, and Hikma's contribution to, talent and education development.

"Public-private and international cooperation is key to ensuring the sustainable growth of worldwide economies in the face of significant oil price shocks, geopolitical tensions and the persistent gap in scientific, technical and human skills," said Darwazeh. "As a rapidly-growing multinational group with markets in more than 50 countries, Hikma is committed to helping communities boost their resilience and adaptability to societal, political and commercial changes, a vision that is reflected in our partnership with the WEF."

+ more
Print page

CR

12 January 2015

Hikma to launch colchicine 0.6mg capsules

London, 12 January 2015 – Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today notes that Takeda Pharmaceuticals U.S.A. Inc. (“Takeda”) has been unsuccessful in appealing the decision by the United States District Court for the District of Delaware to deny Takeda's motion for a preliminary injunction in relation to the distribution of Hikma’s colchicine 0.6mg capsules for the prophylaxis of gout flares in adults. The injunction, which was granted to Takeda on 9 October 2014, has been vacated.

London, 12 January 2015 – Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, today notes that Takeda Pharmaceuticals U.S.A. Inc. (“Takeda”) has been unsuccessful in appealing the decision by the United States District Court for the District of Delaware to deny Takeda's motion for a preliminary injunction in relation to the distribution of Hikma’s colchicine 0.6mg capsules for the prophylaxis of gout flares in adults. The injunction, which was granted to Takeda on 9 October 2014, has been vacated.

Hikma will now prepare to distribute its colchicine, which it will market under the brand name MITIGARE™.  Hikma will also be preparing to launch an authorised generic of MITIGARE™, increasing patient access to this important product.

Said Darwazah, Chairman and CEO of Hikma, said:
“I am very pleased to be launching our colchicine products, demonstrating our success in developing a more differentiated product portfolio for the US market."

According to IMS Health, sales of colchicine in the US market were approximately $688 million for the 12 months ending August 2014.

-- ENDS --

Enquiries:

Hikma Pharmaceuticals PLC  
Susan Ringdal, VP Corporate Strategy and Director of Investor Relations +44 (0)20 7399 2760
Lucinda Henderson, Deputy Director of Investor Relations +44 (0)20 7399 2765
FTI Consulting
Ben Atwell/ Matthew Cole/ Julia Phillips +44 (0)20 3727 1000

About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma operates through three businesses: “Branded”, “Injectables” and “Generics”, based principally in the Middle East and North Africa ("MENA"), where it is a market leader, the United States and Europe.  In 2013, Hikma achieved revenues of $1,365 million and profit attributable to shareholders of $212 million.

Press Release
+ more
Print page

Product

06 November 2014

Board Appointment – Dr Pamela Kirby

London, 6 November 2014 – Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) (OTC: HKMPY) ("Hikma"), the FTSE 250 pharmaceuticals company, is today announcing the appointment of Dr Pamela Kirby as an independent non-executive director of the Company with effect from 1 December 2014.

London, 6 November 2014 – Hikma Pharmaceuticals PLC (LSE: HIK) (DIFX: HIK) (OTC: HKMPY) ("Hikma"), the FTSE 250 pharmaceuticals company, is today announcing the appointment of Dr Pamela Kirby as an independent non-executive director of the Company with effect from 1 December 2014. Dr Kirby will join the Audit, Remuneration and Compliance, Responsibility and Ethics (CRE) Committees.

Said Darwazah, Chairman and Chief Executive, said: "I am delighted that Dr Kirby has agreed to join our Board. She brings a wealth of pharmaceutical, international, strategic, and listed company experience. She has a strong track record from her senior executive and board-level roles, and complements our culture and style perfectly. I am confident that she will enhance the capabilities of the Board, and that we are now in an even stronger position to lead our company going forward."

Dr Pamela Kirby
Dr Pamela Kirby was CEO of Quintiles Transnational Corp and has held senior executive positions in F Hoffmann-La Roche Ltd and AstraZeneca plc. Dr Kirby has chaired Oxford Immunotec Ltd and was senior independent director of Informa plc. Dr Kirby has previously held non-executive director positions with Smith & Nephew plc, Novo Nordisk A/S, Curalogic A/S and Oscient Pharmaceuticals Corp.

Dr Kirby is chairman of Scynexis Inc and a non-executive director of DCC plc and Victrex plc.

Dr Kirby holds a first-class Bachelor of Science degree in Pharmacology and a PhD in Clinical Pharmacology from the University of London.

-- ENDS --

Enquiries:

Hikma Pharmaceuticals PLC  
Peter Speirs, Company Secretary +44 (0)20 7399 2772
Susan Ringdal, Vice President for Investor Relations +44 (0)20 7399 2760
Financial Dynamics
Matthew Cole & Ben Atwell +44 (0)20 3727 1000

Notes to Editors:

About Hikma

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2013, Hikma achieved revenues of $1,365 million and profit attributable to shareholders of $212 million.

Press Release
+ more
Print page

Corporate

06 November 2014

Interim Management Statement

London, 6 November 2014 – Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, is today updating the market on its current trading and financial position. This constitutes its Interim Management Statement relating to the period from 1 July 2014 to date, as required by the UK Listing Authority’s Disclosure and Transparency Rules.

London, 6 November 2014 – Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, is today updating the market on its current trading and financial position. This constitutes its Interim Management Statement relating to the period from 1 July 2014 to date, as required by the UK Listing Authority’s Disclosure and Transparency Rules.

We are pleased to raise our guidance for 2014 to Group revenue growth of around 7%.

Injectables

Our global Injectables business is performing well, as we continue to capture specific market opportunities in the US. Competition is increasing in the US and we expect underlying sales in the second half to be broadly in line with the first half of the year. In MENA, we are seeing a good performance and are on track to deliver slight growth for the full year, while European contract manufacturing sales remain lower this year. Due to the continued strength of specific market opportunities, we are raising our guidance to around 25% revenue growth in 2014, with an adjusted operating margin of above 35%.

Following our acquisition of Bedford Laboratories in July, we also completed the acquisition of the Ben Venue manufacturing site in Bedford, Ohio in September. This will significantly enhance our R&D capabilities and enable us to expand future capacity for injectables manufacturing.

As previously announced, in October 2014 we received a warning letter from the US Food and Drug Administration ("FDA") related to the inspection of our manufacturing facility in Portugal in March 2014. We will work with the FDA to fully resolve all outstanding issues as quickly as possible.

Branded

Revenue in our Branded business is broadly in line with last year. We are delivering good growth in markets such as Egypt and the Gulf Cooperation Council ("GCC") countries, including Saudi Arabia, driven by our strategic focus on newer, higher value products. However, this is being offset by the ongoing restructuring of our business in Algeria and political disruptions, primarily in Iraq and Libya. Overall, we continue to expect the Branded business to deliver low single digit revenue growth for the full year, with an adjusted operating margin of around 21%.

Generics

The Generics business continues to perform very strongly this year, reflecting specific market opportunities and the re-introduction of products. We now expect the Generics business to deliver revenue of around $215 million in 2014, with an adjusted operating margin of around 55%.

On 30 September 2014, we received an approval for a New Drug Application for colchicine 0.6mg capsules by the US FDA, under Section 505(b)(2) of the US Federal Food Drug and Cosmetic Act. On 9 October, the US District Court for the District of Delaware granted Takeda Pharmaceuticals U.S.A., Inc. ("Takeda") a temporary restraining order while the court considered a motion by Takeda for a preliminary injunction. On 5 November, the court denied Takeda's motion but extended the temporary restraining order pending appeal. Our guidance for 2014 does not reflect any contribution from colchicine.

Financing position

Our financing position remains very strong and will enable us to make further strategic acquisitions and investments, as opportunities arise.

Said Darwazah, Chairman and Chief Executive Officer of Hikma said:

“I am pleased with how our businesses are performing this year. The continued strength of our Injectables business reflects the benefit of our broad portfolio and our success in capturing market opportunities. The Generics business continues to perform extremely well this year and we are focused on developing our portfolio and pipeline to support future growth. The Branded business is delivering good growth in a number of important markets and we believe the actions we are taking to restructure our business in Algeria and our commitment to operating in markets impacted by political disruptions, will strengthen our business for the future. ”

Hikma will announce its results for the year ending 31 December 2014 on 11 March 2015.

-- ENDS --

Enquiries:

Hikma Pharmaceuticals PLC  
Susan Ringdal, VP Corporate Strategy and Director of Investor Relations +44 20 7399 2760/
+44 7776 477050
Lucinda Baker, Deputy Director of Investor Relations +44 20 7399 2765/
+44 7818 060211
FTI Consulting
Ben Atwell/ Matthew Cole/ Julia Phillips +44 20 3727 1000

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: “Branded”, “Injectables” and “Generics”, based principally in the Middle East and North Africa ("MENA"), where it is a market leader, the United States and Europe. In 2013, Hikma achieved revenues of $1,365 million and profit attributable to shareholders of $212 million.

Press Release
+ more
Print page

Corporate

23 October 2014

Hikma Meet the Management Day London

London, 23 October 2014 – Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, will host a Meet the Management Day in London on Tuesday 2 December 2014.

London, 23 October 2014 – Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), the fast growing multinational pharmaceutical group, will host a Meet the Management Day in London on Tuesday 2 December 2014.

The event will take place at The Westbury Hotel, 2nd Floor Westbury Gallery, Bond Street, London, W1S 2YF from 9.30am through to 2.30pm.

Our confirmed Management for the event are listed below. Hikma Management will be spread out across 4 meeting rooms and investors & analysts will rotate rooms to meet everyone in 4 Q&A slots.

Corporate Focus:
Said Darwazah, Chairman & CEO
Bassam Kanaan, Chief Strategy & Corporate Development Officer
Khalid Nabilsi, CFO

MENA Focus:
Mazen Darwazah, President & CEO MENA and Emerging Markets
Salah Mawajdah, Head of MENA
Hassan Shafiq, Managing Director, Hikma Egypt
Basel Ziyadeh, General Manager / GCC
Ma'moon Araidah, Senior Director of Sales & Marketing / MENA

US Generics Focus:
Mike Raya, CEO West-Ward Pharmaceuticals
Brian Hoffman, VP Corporate Development West-Ward Pharmaceuticals
Fadi Nassar, Corporate VP API
Spiro Gavaris, VP Sales and Marketing West-Ward Pharmaceuticals

Injectables Focus:
Riad Mishlawi, Vice President & Global Head of Injectables
Bashar Shomali, Vice President EU and Global Injectables
Natheer Masarweh, VP Quality Global Injectables and Operations (Portugal)

If you are interested in attending this event please contact Kate Komornicka kate@hikma.uk.com to register your interest and for further details.

-- ENDS --

Enquiries:

Hikma Pharmaceuticals PLC  
Susan Ringdal, VP Corporate Strategy and Director of Investor Relations +44 (0)20 7399 2760/
+44 7776 477050
Lucinda Henderson, Deputy Head of Investor Relations +44 (0)20 7399 2765/
+44 7818 060211
FTI Consulting
Ben Atwell/ Matthew Cole/ Julia Phillips +44 (0)20 3727 1000

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma operates through three businesses: “Branded”, “Injectables” and “Generics”, based principally in the Middle East and North Africa ("MENA"), where it is a market leader, the United States and Europe. In 2013, Hikma achieved revenues of $1,365 million and profit attributable to shareholders of $212 million.

Press Release
+ more
Print page

Corporate

18 October 2014

Hikma Pharmaceuticals Launches ‘You Are Hikma’ 2014 Campaign

Amman, October 2014 – Hikma Pharmaceuticals, Jordan’s leading pharmaceutical manufacturer, held its annual employee welfare week “You Are Hikma” campaign to boost health and workplace safety. This year’s campaign under the slogan “Let’s work together for a safer and greener environment” was conducted at Hikma Pharmaceuticals headquarters in Amman, and at its subsidiary the Arab Pharmaceuticals Manufacturing company (APM) in Salt.

Amman, October 2014 – Hikma Pharmaceuticals, Jordan’s leading pharmaceutical manufacturer, held its annual employee welfare week “You Are Hikma” campaign to boost health and workplace safety. This year’s campaign under the slogan “Let’s work together for a safer and greener environment” was conducted at Hikma Pharmaceuticals headquarters in Amman, and at its subsidiary the Arab Pharmaceuticals Manufacturing company (APM) in Salt.

An international initiative staged at Hikma locations worldwide, ‘You Are Hikma’ celebrates the company’s core values by raising awareness among its staff on health, safety and environmental issues. With more than 350 participants, the campaign this year included a range of activities such as medical testing for the employees, blood drive, awareness lectures on work-related injuries, proper use of antibiotics, safe use of drugs, safe handling of materials and forklift training. Moreover, Hikma employees participated in the “Clean Up the World” activity of the Royal Society for the Conservation of Nature (RSCN), which took place in Dibeen Forest on October 18.

Hana Ramadan, Vice President of Corporate Communication at Hikma Pharmaceuticals, said, “‘You Are Hikma’ falls within the umbrella of Hikma’s corporate responsibility strategy that revolves around two major themes: Education and Well-Being. It emphasizes who we are as an organisation – ethical in our operations and dedicated to improving our employee’s quality of life and personal empowerment, through positive and valuable educational and environmental activities”.

+ more
Print page

CR

Get adobe reader Most computers will open PDF documents automatically, but you may need to download Adobe Reader.